インスリン抵抗性とインシデントうつ病のリスク:年齢,血糖状態,および前向きなコホート研究における肥満の役割
Dae Jong Oh1, Chaiho Jeong2, Junhyung Kim1,3
1Workplace Mental Health Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
The Lancet regional health. Western Pacific
|September 2, 2025
まとめ
インスリン抵抗性では,特に若い成人では,うつ病のリスクが増加します. インスリン抵抗性の早期スクリーニングと管理は,特にリスクグループにおいて,うつ病の発生率を減らすのに役立ちます.
科学分野:
- メタボリック・ヘルス
- 精神科
- 流行病学
背景:
- インスリン抵抗性 と うつ病 の 関係 に つい て は 議論 が あり ます.
- この研究では,インスリン抵抗性が新発症うつ病の危険因子として調査されています.
研究 の 目的:
- インスリン抵抗性とうつ病の発症リスクの上昇を判断する.
- このアソシエーションのモダレーターを特定する.
主な方法:
- 韓国人成人の233,452人を対象とした多中心的な前向きなコホート研究.
- インスリン抵抗性のホメオスタシスモデル評価 (HOMA- IR) によるインスリン抵抗性の評価
- 流行病学研究センターのうつ病スケール (CES- D) により定義されたインシデントうつ病のスコアは≥16です.
主要な成果:
- HOMA- IRとうつ病のリスクとの間には,用量依存の関連性が見られた (HR=1. 15).
- この関連性は,40歳未満の成人,高血糖症,体重増加,低筋脂肪比で強く見られた.
- 1,124,268人/年に 38,801人のうつ病が確認された.
結論:
- インスリン抵抗性は,うつ病の修正可能な危険因子である可能性があります.
- インスリン抵抗性の早期スクリーニングと管理は,特に脆弱な集団におけるうつ病の予防に重要である.
関連する概念動画
Diabetes: Symptoms, Diagnosis, and Complications
685
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
685
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Psychoneuroimmunology: Diabetes and Cancer
62
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
62
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288


